• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Appoints Karen Flynn to Board of Directors

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    $WST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTLT alert in real time by email

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.

    Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer health products. Prior to this, she held the positions of Chief Commercial Officer and President of Biologics at Catalent. Prior to Catalent, she served as Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services (NYSE:WST), and as President of its Pharmaceutical Packaging Systems business. In addition to her experience leading high-growth businesses, Ms. Flynn brings an extensive background in commercial strategy, strategic planning and innovation and quality management.

    "We are excited to welcome Karen to our Board of Directors," said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. "Karen's extensive commercial expertise in pharmaceutical services will serve as a tremendous asset as we continue to grow. Additionally, her strong Board leadership and governance experience will be valuable as we advance as a public company."

    Ms. Flynn currently serves on the Board of Directors of Quanterix Corporation (NASDAQ:QTRX), where she is a member of the Compensation and Nominating and Governance Committees and on the Board of Directors of Catalent. She has also served on the Board of Recro Pharma, Inc., a specialty pharma and contract development and manufacturing organization, where she was Chair of the Compensation Committee and a member of the Audit Committee.

    Ms. Flynn holds a Master of Science in Engineering from University of Pennsylvania and a Master of Science in Business Administration from Boston University. She completed her Bachelor of Science at the University of Notre Dame.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Contacts

    Jason Peterson

    Vice President & Treasurer, Sotera Health

    [email protected]

    Kristin Gibbs

    Chief Marketing Officer, Sotera Health

    [email protected]

    Source: Sotera Health Company



    Primary Logo

    Get the next $CTLT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTLT
    $QTRX
    $SHC
    $WST

    CompanyDatePrice TargetRatingAnalyst
    Quanterix Corporation
    $QTRX
    8/11/2025$5.00Buy → Hold
    Canaccord Genuity
    West Pharmaceutical Services Inc.
    $WST
    6/24/2025$245.00Equal Weight
    Barclays
    Sotera Health Company
    $SHC
    5/5/2025$17.00Neutral → Buy
    Goldman
    West Pharmaceutical Services Inc.
    $WST
    3/18/2025$275.00Outperform
    Evercore ISI
    West Pharmaceutical Services Inc.
    $WST
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    West Pharmaceutical Services Inc.
    $WST
    1/8/2025$400.00Buy
    Citigroup
    West Pharmaceutical Services Inc.
    $WST
    12/13/2024Peer Perform
    Wolfe Research
    West Pharmaceutical Services Inc.
    $WST
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    More analyst ratings

    $CTLT
    $QTRX
    $SHC
    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quanterix downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $5.00

    8/11/25 9:55:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Barclays initiated coverage on West Pharm with a new price target

    Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00

    6/24/25 8:11:45 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sotera Health upgraded by Goldman with a new price target

    Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

    5/5/25 8:27:32 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mcmahon Robert W.

    3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    8/12/25 7:21:15 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by SVP & Chief Financial Officer Mcmahon Robert W.

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    8/12/25 7:19:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 11,508 shares, decreasing direct ownership by 6% to 189,602 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    8/7/25 6:09:02 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadership team will present at the Canaccord Genuity 45th Annual Growth Conference in Boston, Massachusetts on Tuesday, August 12th, at 3:30 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at www.quanterix.com. A replay of the webcast will be available for a limited period following the conference. About Quanterix Quanterix is a global leader in ultra-sensi

    8/11/25 7:00:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Quanterix Releases Financial Results for the Second Quarter of 2025

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. "Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market," said Masoud Toloue, CEO of Quanterix. "We have built a franchise that is generating approximately $100 million of consumables revenue, on a pro forma basis, and demonstrating resiliency in the face of near-term challenges in the US academic market. Within the quarter, our Accelerator business reported a net i

    8/7/25 4:06:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Quanterix Corporation

    SCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)

    8/13/25 4:10:08 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form PRE 14A filed by Quanterix Corporation

    PRE 14A - Quanterix Corp (0001503274) (Filer)

    8/8/25 5:15:54 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Sotera Health Company

    10-Q - Sotera Health Co (0001822479) (Filer)

    8/8/25 4:19:13 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/13/25 4:39:15 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/10/25 4:08:44 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/9/25 5:44:04 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Leadership Updates

    Live Leadership Updates

    View All

    West Welcomes Robert McMahon as Incoming Chief Financial Officer

    EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.   "Bob is an accomplished CFO and business executive within the

    7/21/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

    Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets. Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards. Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said

    7/8/25 9:07:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    3/19/25 4:10:00 PM ET
    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalent Inc.

    SC 13G/A - Catalent, Inc. (0001596783) (Subject)

    11/14/24 4:35:03 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Financials

    Live finance-specific insights

    View All

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Quanterix Releases Financial Results for the Second Quarter of 2025

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. "Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market," said Masoud Toloue, CEO of Quanterix. "We have built a franchise that is generating approximately $100 million of consumables revenue, on a pro forma basis, and demonstrating resiliency in the face of near-term challenges in the US academic market. Within the quarter, our Accelerator business reported a net i

    8/7/25 4:06:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 7, 2025, at 4:30 p.m. E.T., to discuss its second quarter 2025 financial results. Quanterix will issue a press release regarding its second quarter 2025 financial results prior to the conference call on Thursday, August 7, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 5591565. Interested investors can also access

    8/4/25 4:02:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials